Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
- Registration Number
- NCT02242838
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The primary objective of this survey is to prospectively investigate safety and efficacy in patients with hypertension treated with telmisartan in proper use in medical practice over a long period
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6336
Inclusion Criteria
- Patients with hypertension
Exclusion Criteria
Patients with the following conditions
- Patients with a history of hypersensitivity of this product
- Women in pregnancy (included the possibility of pregnancy)
- Patients with severe biliary obstructive disorders or severe hepatic insufficiency
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hypertensive patients Telmisartan -
- Primary Outcome Measures
Name Time Method Change in Mean systolic blood pressure (SBP) up to 1 year Number of patients with adverse drug reactions up to 1 year Change in Mean diastolic blood pressure (DBP) up to 1 year Incidence of adverse drug reactions up to 1 year classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology
- Secondary Outcome Measures
Name Time Method Overall assessment of efficacy by investigator on 4-point scale at 3 month, after 1 year Change in pulse rate up to 1 year